Concepedia

Patrycja Olszynski

PO

Statistics

Publications

3

Citations

141

H-Index

3

Active since

2008

Affiliations

Dana-Farber Cancer Institute(Current)

The University of Texas MD Anderson Cancer Center

Moffitt Cancer Center

Exelixis (United States)

University of California, San Francisco

Patrycja Olszynski is an author at Dana-Farber Cancer Institute specializing in medicine, jak inhibitor therapy, and jak-stat signaling pathway.

Publications per year

2008–2016

3

Publications

3

A Phase I Study of XL019, a Selective JAK2 Inhibitor, in Patients with Primary Myelofibrosis, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis

Neil P. Shah, Patrycja Olszynski, Lubomir Sokol et al. · Blood · 2008 · 68 citations

, , +7

Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor

Srđan Verstovšek, Constantine S. Tam, Martha Wadleigh et al. · Leukemia Research · 2013 · 42 citations · Full text

, , +7

Quadratus lumborum catheters for breast reconstruction requiring transverse rectus abdominis myocutaneous flaps

Nicole Z. Spence, Patrycja Olszynski, Anne Lehan et al. · Journal of Anesthesia · 2016 · 31 citations

, , +16

1–3 of 3